An inactivating mutation of the tumor suppressor genes, TSC1 or TSC2, leads to the mammalian target of rapamycin complex 1 (mTORC1) activation causing increased cell growth, making rapamycin and its analogs (like sirolimus) valuable treatment options for LAM [8]. Here, TSC2 is linked to lymphangioleiomyomatosis.